Effects of Vitamin D on Inflammation in Liver Disease

Inclusion Criteria: * Men or women aged 18 or older * Total 25-OH Vit D \< 25 ng/mL * Infection with HCV genotype 1 (subjects infected with multiple genotypes are not eligible). * Plasma HCV RNA concentration of \>100,000 IU/mL. * HCV-infected subjects naïve to treatment: subjects who either have never been treated for HCV infection or who previously received HCV treatment ending \> 3 months prior to enrollment (including, any IFN-Alpha with or without ribavirin, or other anti-HCV antiviral medication). Exclusion Criteria: * Women who are pregnant or breastfeeding. * Patients with Sarcoidosis, Histoplasmosis, Lymphoma, Primary Hyperparathyroidism or Idiophatic Hypercalcemia. * Liver Cirrhosis. * Known active gastrointestinal disease that could interfere with the absorption of the test article. * Laboratory determinations at screening as follows: * Hemoglobin \<10 g/dL . * Serum creatinine that is not within normal limits. However, such subjects may be enrolled if the Cockroft-Gault glomerular filtration rate (GFR) is \> 50 mL/minute. * Unstable hypertension, cardiac disease or type 2 diabetes requiring changes in treatment with medications 4 weeks prior to screening or during the screening period. * Use of an investigational drug within 4 weeks before the screening visit or during the screening period. * Use of systemic immunosuppressants (including systemic, oral, or intravenous corticosteroids) or immunomodulating agents within 4 weeks before the screening visit or during the screening period.